Document is current
Any future updates will be listed below
-
Authors
Krinner, Axel https://orcid.org/0009-0001-7285-0448
Schultze, Michael
Marijam, Alen https://orcid.org/0000-0003-1046-9702
Pignot, Marc https://orcid.org/0000-0002-1883-4113
Kossack, Nils https://orcid.org/0000-0002-9521-3898
Mitrani-Gold, Fanny S. https://orcid.org/0000-0001-8829-7088
Joshi, Ashish V. https://orcid.org/0000-0002-7089-1545
-
Funding
Funding for this research was provided by:
GlaxoSmithKline (Study number 214846)
- License Information
-
More Information
Article History
Received: 11 December 2023
Accepted: 4 April 2024
First Online: 13 June 2024
Declarations
:
: Axel Krinner is an employee of WIG2 which received funding from GSK to conduct this study. Michael Schultze is an employee of ZEG Berlin which received funding from GSK to conduct this study. Alen Marijam is an employee of and shareholder in GSK. Marc Pignot is an employee of ZEG Berlin which received funding from GSK to conduct this study. Nils Kossack is an employee of WIG2 which received funding from GSK to conduct this study. Fanny S. Mitrani-Gold is an employee of and shareholder in GSK. Ashish V. Joshi is an employee of and shareholder in GSK.
: The study complied with all applicable laws regarding subject privacy. Study results are presented as aggregate analyses that do not allow for subject identification, thus informed consent and ethics committee and Institutional Review Board approvals were not required. This study was conducted in accordance with the protocols and consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, International Council on Harmonization Good Clinical Practice Guidelines, and applicable laws and regulations. Permission was granted to access the databases utilised in this study.
